Press Releases

A small molecule discovered and developed by a team of scientists led by Fengzhi Li, PhD, Associate Professor of Oncology in the Department of Pharmacology and Therapeutics at Roswell Park Comprehensive Cancer Center, eliminates human pancreatic and colorectal tumor cells by binding to and degrading DDX5, a powerful cancer-causing protein. The latest research results from Dr. Li’s lab, published today in Clinical and Translational Medicine, suggests that FL118, a compound derived from Chinese tree bark, could be further developed into a targeted treatment for pancreatic cancer and colon cancer, and possibly for other solid and liquid tumors as well.

A multidisciplinary team from Roswell Park Comprehensive Cancer Center has uncovered a previously unknown function of a gene that regulates p53, a protein that plays a significant role in more than half of all cancers. Their findings, published this week in the journal PlosGenetics, could have big implications for the development of cancer therapies targeting MDM2.

Patients with head and neck cancer undergoing radiation therapy are less likely to require opioids or a feeding tube if they received a higher dose of prophylactic gabapentin before their treatment, findings from a team of radiation oncologists at Roswell Park Comprehensive Cancer Center show. Their discovery, published today in JAMA Network Open, suggests that a prophylactic, or preventative, gabapentin dose of 3600 mg daily can delay or eliminate the need for opioids to manage the pain associated with radiation-induced oral mucositis in patients with head and neck cancer.

Radical prostatectomy, or removal of the prostate gland and surrounding tissues, is a standard surgical procedure used to treat men with prostate cancer. Robot-assisted radical prostatectomy (RARP) is becoming increasingly common, but as with other radical prostatectomy methods, urinary incontinence and erectile dysfunction are common complications of the procedure.

Cancer is the most dangerous threat to firefighter health and safety today, surpassing cardiac related deaths. To help address and reduce these risks, the Buffalo Fire Department and Roswell Park Comprehensive Cancer Center have teamed up to develop an ongoing initiative to keep first responders safe.

Roswell Park specialists will share the latest advances and developments in the treatment of blood-related cancers at the 2022 Tandem Transplantation & Cellular Therapy Meetings of American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah, from April 23 to 26.

Join Roswell Park Comprehensive Cancer Center’s Center for Indigenous Cancer Research (CICR) for a webinar on Tuesday, April 26, at 3 p.m. EST featuring National Institutes of Health (NIH) Tribal Health Research Office Director David R. Wilson, PhD.